piwik-script

Intern
    Onkologische Forschung

    AG Schirbel

    Andreas Schirbel: Theranostics

    Our group aims to develop and establish theranostic radiopharmaceuticals for personalized endoradiotherapy. We have already successfully established the following theranostic radiopharmaceuticals in our clinic:

    1. DOTATOC targeting neuroendocrine tumours
    2. PSMA I&T targeting prostate carcinoma
    3. CXCR4 targeting chemokine expressing tumours
    4. IMAZA targeting adrenocortical carcinoma

    All therapies provide efficacious treatment and only few adverse effects are observed. The preparation of clinical trials and the development of further theranostic pairs is subject of our ongoing research. Theranostic radiopharmaceuticals that selectively inhibit fibroblast activating protein (FAP) or the enzyme CYP17 are currently in preclinical development.

    Recent Publications (extract)

    Reiter T., Kircher M., Schirbel A., Werner R.A., Kropf S., Ertl G., Buck A.K., Wester H.J., Bauer W.R., Lapa C.; Imaging of C-X-C Motif Chemokine Receptor CXCR4 Expression After Myocardial Infarction With Pentixafor-PET/CT in Correlation With Cardiac MRI. JACC: Cardiovascular Imaging 11 (2018) 1541-1543.

    Lapa C., Lückerath K., Kircher S., Hänscheid H., Grigoleit G.U., Rosenwald A., Stolzenburg A., Kropf S., Einsele H., Wester H.J., Buck A.K., Kortüm K.M., Schirbel A.; Potential influence of concomitant chemotherapy on CXCR4 expression in receptor directed endoradiotherapy. Br. J. Haematol. 148 (2019) 440-443.

    Hänscheid H., Hartrampf P.E., Schirbel A., Buck A.K., Lapa C.; Intraindividual comparison of Lu-DOTA-EB-TATE and Lu-DOTA-TOC. Eur. J. Nucl. Med. Mol. Imaging 48 (2021) 2566-2572.

    Duell J., Krummenast F., Schirbel A., Klassen P., Samnick S., Rauert-Wunderlich H., Rasche L., Buck A.K., Wester H.J., Rosenwald A., Einsele H., Topp M.S., Lapa C., Kircher M.; Improved Primary Staging of Marginal-Zone Lymphoma by Addition of CXCR4-Directed PET/CT. J. Nucl. Med. 62 (2021) 1415-1421.

    Heinze B., Schirbel A., Nannen L., Michelmann D., Hartrampf P.E., Bluemel C., Schneider M., Herrmann K., Haenscheid H., Fassnacht M., Buck A.K., Hahner S.; Novel CYP11B-ligand IMAZA as promising theranostic tool for adrenocortical tumors: comprehensive preclinical characterization and first clinical experience. Eur J Nucl Med Mol Imaging. (2021)  doi: 10.1007/s00259-021-05477-y. In press.